LinkedIn image ad examples

Discover how agentic AI coordinates clinical workflows, reduces delays and manual effort to help you execute trials faster with confidence.

Every instrument result typed into a sample record by hand needs a second check. CaliberLIMS pulls results straight from your instruments into the right sample record. It can save more than 30% of an analyst’s time. Explore how CaliberLIMS connects to your instruments.

How an oncology pathway cut unplanned ED presentations by 72%. Patients reported symptoms between cycles; triage ran automatically against the protocol.

How a pulmonary rehab pathway kept patient engagement above 80%. Automated prompts, symptom checks and oxygen alerts kept patients on program.

Biomat manufactures High and Medium Binding plates for Immunoassays in Italy, with a direct line to production. 30+ years of Expertise in Surface Modification.

We have developed 29+ Surfaces to answer any Immunoassay needs when High and Medium binding surfaces are not enough.

Je merkt dat er iets wringt. Als werkgever hoef je geen diagnose te stellen, maar niets doen helpt niemand. Op tijd schakelen wel!

Je ziet het vaak sneller dan de cliënt het benoemt. Als professional wil je niet wachten tot alles ontspoort. Je zoekt een plek waar cliënten discreet terechtkunnen. Affect2U ondersteunt herstelgericht en werkt vlot samen met doorverwijzers.

Välkommen till Capio Vårdcentral Broby och Borrby – två mindre vårdcentraler med stort hjärta, nära samarbete och hög teamkänsla.

💡 Does your analytical instrument lose sensitivity over time? Pressure fluctuations in the gas feeding an ionization source or carrier line often show up downstream as inconsistent ionization, poor sensitivity, or unreliable data. 👉️ The CHIPREG Electronic Pressure Controller: 1️⃣ Gives each gas line independent, 2️⃣ Real-time pressure regulation. 3️⃣ Steady pressure regardless of upstream fluctuations. 4️⃣ Footprint of just 14 x 35 x 47 mm. When flow is the critical parameter, the IMI Mass Flow Controller is often the better choice. It controls the required gas flow directly instead of the pressure. It also compensates automatically for clogging, tubing and fitting changes, and environmental variations, which helps keep performance and sensitivity consistent over time. If you want to learn more about our CHIPREG EPC and MFC, please visit: https://lnkd.in/e-t7yTZf #IMI #EngineeringExcellence #PressureControl #GasControl

Many labs face pressure to deliver more results with the same people, budget, and bench space. The teams pulling ahead often focus on measurable gains in four areas: throughput, cost, risk reduction, and sustainability improvements. CrossLab Connect supports lab-wide visibility so you can see every instrument, understand workflow performance, and identify where your lab loses time before bottlenecks build.

Practical guidance to reduce variability in your lab workflow.

Psychiater gezocht voor de polikliniek Jongvolwassenen in Haarlem. Werk in een enthousiast, innovatief en goed georganiseerd multidisciplinair team. 8 tot 24 uur per week, salaris tot € 11.292 bruto per maand.

Enterprise streaming performance shouldn't require a full PACS replacement. StreamVue layers onto the PACS you already run — over standard DICOM, no migration, deployed in days. Diagnostic-grade speed without touching your infrastructure.

Your dashboards show every signal. They don't tell you which one matters, who should act, or how much time you have left to intervene. Join CluePoints, IQVIA and CRScube on November 10 to see how an AI-powered Clinical Data Control Tower turns fragmented trial signals into coordinated decisions.

Most data quality issues are visible long before they become problems. This session shows how control towers combine eSource, labs and EDC with risk-based intelligence to flag site-level issues early, with human oversight scaled to risk. Register for the November 10 webinar.

Home care demand is growing, but opportunity looks different in every market. A Place for Mom can help you understand where families are actively searching for care and where opportunities for growth may exist. See what we're seeing in your market.

Lab budgets are tight. Growth Rewards puts money back into your lab as you shift purchases to Genesee. Fill out the form to talk with a sales rep.

360biolabs is Australia's most comprehensive bioanalytical laboratory, providing a diverse range of assay services to support clinical trials programs of new therapeutics, vaccines and diagnostics in a quality-assured environment. We offer a full suite of pharmacokinetic (PK) and pharmacodynamic (PD) endpoints, including small and large molecule PK, ADA, nAb, biomarkers (MSD, ELISA, SIMOA, Luminex, ELISpot), flow cytometry, immunology, molecular and virology assays, supported by globally recognised quality systems under GLP, GCP and ISO/IEC 17025. With a decade of Enabling Future Medicines, 360biolabs has built world-class bioanalytical excellence advancing global clinical research.

Behavioral health doesn't run on a referral. The person decides on their own and makes the call. It isn't one yes, it's five, and any one of them can stall. Six things AI has to get right to support that moment.

🔬Webinar Invitation: Analysis of Dimeric Activin E in Biological Samples Activin E is an emerging therapeutic target for obesity and metabolic diseases. Reliable quantification of circulating dimeric Activin E is essential for supporting pharmacodynamic studies in drug development. In this webinar, discover how a dimer-specific Activin E ELISA was developed and validated, with its performance compared against LC-MS/MS using human serum samples. What you’ll learn: 🔹 Development and validation of a dimeric Activin E ELISA 🔹 Assessment of assay accuracy and specificity 🔹 Comparison with LC-MS/MS 🔹 Pharmacodynamic evaluation in human and NHP siRNA models 🎥 Click to Register: https://lnkd.in/gZ8B-Va3/?utm_campaign=EU_Keyproducts&utm_source=linkedin&utm_medium=paid&utm_id=818919203&hsa_acc=514352614&hsa_cam=818919203&hsa_grp=912846566&hsa_ad=1644569646&hsa_net=linkedin&hsa_ver=3

𝗘𝘂𝗿𝗼𝗽𝗲’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗴𝗹𝗼𝗯𝗮𝗹 𝗛𝗜𝗩 𝗿𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: 𝗔𝗜𝗗𝗦 𝗶𝘀 𝗻𝗼𝘁 𝗼𝘃𝗲𝗿 Since 2011, HIV disbursements from European donor governments to low- and middle-income countries have fallen by 58%, according to UNAIDS. Through our 𝗔𝗜𝗗𝗦 𝗜𝘀 𝗡𝗼𝘁 𝗢𝘃𝗲𝗿 𝗰𝗮𝗺𝗽𝗮𝗶𝗴𝗻, we’re calling on European governments to renew their commitments. New pledges must translate into predictable funding for prevention, testing, treatment and community-led services. Europe must help ensure that people everywhere can access the HIV services they need. Governments must act urgently to strengthen international support, alongside sustained domestic investment in the countries most affected. We must prevent new HIV transmissions, close treatment gaps, and improve retention in care. Solidarity is essential if we are to ensure services reach the people who need them. 𝗧𝗵𝗲 𝗵𝘂𝗺𝗮𝗻 𝗰𝗼𝘀𝘁 𝗼𝗳 𝗶𝗻𝗮𝗰𝘁𝗶𝗼𝗻 𝗶𝘀 𝘂𝗻𝗮𝗰𝗰𝗲𝗽𝘁𝗮𝗯𝗹𝘆 𝗵𝗶𝗴𝗵. 𝗦𝗶𝗹𝗲𝗻𝗰𝗲 = 𝗗𝗲𝗮𝘁𝗵. #AIDSIsNotOver 👉 𝗛𝗲𝗹𝗽 𝗸𝗲𝗲𝗽 𝗛𝗜𝗩 𝗼𝗻 𝘁𝗵𝗲 𝗮𝗴𝗲𝗻𝗱𝗮. Follow AHF Europe on LinkedIn for stories, campaigns and advocacy updates from Europe and beyond. 📷 Candlelight vigil in Thessaloniki, Greece. Standing together with our partner Positive Voice (Θετική Φωνή) #AHFEurope #HIV #HealthEquity #HumanRights The Global Fund | European Commission | WHO Regional Office for Europe | HIV Prevention Alliance

Just a 30% reduction in lower-limb ulcer admissions in England means 27 fewer admissions every single day. This is the prize hidden within Hospital Episode Statistics (HES), the NHS’s own admissions data that almost no Trust ever sees. It shows what impact can be made if we heal wounds earlier and more durably: fewer readmissions, fewer emergencies, fewer amputations, increased bed capacity, and millions of pounds saved. And the therapies to deliver exactly this already exist: evidence-based options such as Topical Wound Oxygen (TWO₂®) therapy, recommended in the latest NICE guidelines for non-healing diabetic foot ulcers and listed on the NHS Supply Chain. Data this clear and therapies this proven are a powerful combination, and the opportunity to make substantive change is there to be taken. Take a closer look at the national NHS picture and request figures from AOTI for your own Trust. Let’s turn HES data into action.

A 30% reduction in amputations among lower-limb ulcer patients in England means over 2,500 fewer amputations each year, saving the NHS over £15 million. This is the prize hidden within Hospital Episode Statistics (HES), the NHS’s own admissions data that almost no Trust ever sees. It shows what impact can be made if we heal wounds earlier and more durably: fewer readmissions, fewer emergencies, fewer amputations, increased bed capacity, and millions of pounds saved. And the therapies to deliver exactly this already exist: evidence-based options such as Topical Wound Oxygen (TWO₂®) therapy, recommended in the latest NICE guidelines for non-healing diabetic foot ulcers and listed on the NHS Supply Chain. Data this clear and therapies this proven are a powerful combination, and the opportunity to make substantive change is there to be taken. Take a closer look at the national NHS picture and request figures from AOTI for your own Trust. Let’s turn HES data into action.